Cargando…
PlGF–MMP9-engineered iPS cells supported on a PEG–fibrinogen hydrogel scaffold possess an enhanced capacity to repair damaged myocardium
Cell-based regenerative therapies are significantly improved by engineering allografts to express factors that increase vascularization and engraftment, such as placental growth factor (PlGF) and matrix metalloproteinase 9 (MMP9). Moreover, the seeding of therapeutic cells onto a suitable scaffold i...
Autores principales: | Bearzi, C, Gargioli, C, Baci, D, Fortunato, O, Shapira-Schweitzer, K, Kossover, O, Latronico, M V G, Seliktar, D, Condorelli, G, Rizzi, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944231/ https://www.ncbi.nlm.nih.gov/pubmed/24525729 http://dx.doi.org/10.1038/cddis.2014.12 |
Ejemplares similares
-
PlGF, immune system and hypertension
por: Carnevale, Daniela, et al.
Publicado: (2015) -
PlGF Immunological Impact during Pregnancy
por: Albonici, Loredana, et al.
Publicado: (2020) -
A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome
por: Stepan, H., et al.
Publicado: (2016) -
sFLT1, PlGF, the sFLT1/PlGF Ratio and Their Association with Pre-Eclampsia in Twin Pregnancies—A Review of the Literature
por: Sapantzoglou, Ioakeim, et al.
Publicado: (2023) -
Changes in concentrations of melatonin, PlGF, and cytokines in women with preeclampsia
por: Savka, Ruslan Florovych, et al.
Publicado: (2023)